Travere Therapeutics ALERT: Securities Fraud Investigation by Block & Leviton Could Allow TVTX Investors to Recover Losses

Core Viewpoint - Block & Leviton is investigating Travere Therapeutics, Inc. for potential securities law violations following a significant drop in its stock price after the FDA extended the review timeline for its drug FILSPARI [2][4]. Group 1: Company Overview - Travere Therapeutics, Inc. is facing scrutiny after its shares were halted from trading due to a more than 30% decline in intraday trading on January 13, 2026 [2]. - The U.S. FDA has set a new PDUFA target action date of April 13, 2026, for the supplemental New Drug Application for FILSPARI, indicating that additional data is required to assess clinical benefits [2]. Group 2: Investigation Details - Block & Leviton is examining whether Travere Therapeutics adequately disclosed the risks associated with the FDA review extension and if prior communications were misleading [2][4]. - The firm is considering filing an action to recover losses for investors who have been affected by the stock price decline [4]. Group 3: Investor Eligibility - Any investor who purchased common stock of Travere Therapeutics and experienced a loss may be eligible to participate in the investigation, regardless of whether they have sold their shares [3]. Group 4: Whistleblower Information - Individuals with non-public information about Travere Therapeutics are encouraged to assist in the investigation or report to the SEC under the whistleblower program, with potential rewards of up to 30% of any successful recovery [6]. Group 5: Firm Reputation - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [7].